AIO-NET-0113
A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome (CS) Refractory to Somatostatin Analog (SSA) Therapy
III
Status: Rekrutierung beendet
Zeitraum
2013
2014
Zentren
Keine Zentren gesucht
14.04.2022
Identifier
AIO-NET-0113
Kontakt
Ansprechpartner*in
Prof. Dr. med. Marianne Pavel
E-Mail marianne.pavel@uk-erlangen.de